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ARTICLE
A molecular mechanism for transthyretin
amyloidogenesis
Ai Woon Yee 1,2, Matteo Aldeghi 3, Matthew P. Blakeley 2, Andreas Ostermann 4, Philippe J. Mas5,
Martine Moulin1,2, Daniele de Sanctis6, Matthew W. Bowler 7, Christoph Mueller-Dieckmann6,
Edward P. Mitchell1,6, Michael Haertlein2, Bert L. de Groot3, Elisabetta Boeri Erba5 & V. Trevor Forsyth1,2
Human transthyretin (TTR) is implicated in several fatal forms of amyloidosis. Many muta-
tions of TTR have been identified; most of these are pathogenic, but some offer protective
effects. The molecular basis underlying the vastly different fibrillation behaviours of these
TTR mutants is poorly understood. Here, on the basis of neutron crystallography, native mass
spectrometry and modelling studies, we propose a mechanism whereby TTR can form
amyloid fibrils via a parallel equilibrium of partially unfolded species that proceeds in favour of
the amyloidogenic forms of TTR. It is suggested that unfolding events within the TTR
monomer originate at the C-D loop of the protein, and that destabilising mutations in this
region enhance the rate of TTR fibrillation. Furthermore, it is proposed that the binding of
small molecule drugs to TTR stabilises non-amyloidogenic states of TTR in a manner similar
to that occurring for the protective mutants of the protein.
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Human transthyretin (TTR) is a 55 kDa homotetramericprotein that transports thyroxine (T4) and retinol-bindingprotein (RBP) in the serum and cerebrospinal fluid
(Fig. 1a–c). Wild-type (WT) TTR is intrinsically amyloidogenic,
and causes amyloid fibril formation in elderly individuals,
resulting in senile systemic amyloidosis (SSA)1,2. A large number
( > 100) of TTR mutants have been identified (http://
amyloidosismutations.com). The majority of these are impli-
cated in familial amyloid polyneuropathy/myocardiopathy (FAP/
FAC) and several other forms of amyloidosis3–5. Of special
interest are the T119M and S52P mutations. The T119M muta-
tion is non-amyloidogenic, and heterozygous individuals carrying
the T119M mutation and an amyloidogenic mutation, such as
V30M, either remain asymptomatic of FAP or present a more
benign form of the disease6,7. On the other hand, individuals
carrying the S52P mutation develop aggressive and early-onset
fatal amyloidosis8,9. Currently, only one drug—tafamidis (trade
name Vyndaqel; Pfizer)—has been granted market authorisation
for the treatment of TTR-FAP in adult patients having stage
1 symptomatic polyneuropathy10.
Considerable effort has been invested in seeking to identify the
factors that underlie TTR amyloid formation including X-ray
diffraction11–13, NMR14–16, solution scattering17, and mass
spectrometry (MS)18. However, a molecular level understanding
of the widely different behaviours of various TTR mutants has
remained elusive11,12. In this paper, native MS, neutron crystal-
lography, and computer simulations have been used to investigate
the effects of the T119M and S52P mutations on TTR stability
and the molecular determinants of amyloid formation. It is found
that the S52P mutation destabilises TTR by altering the stability
of the CD loop in the protein monomer. In contrast, the T119M
mutation stabilises the dimer–dimer interface as well as TTR’s
tertiary structure. Furthermore, it is shown how the stability of
TTR tetramers is coupled to those of the monomers and dimers.
Finally, it is suggested that tafamidis stabilises native tetrameric
TTR in a similar way to that occurring for the T119M mutant in
terms of thermodynamic, kinetic and structural features. A
molecular mechanism is proposed by which the vastly different
behaviours of the various TTR mutants can be understood.
Results
Kinetics of TTR tetramer dissociation. Tetramer dissociation is
thought to be the rate-limiting step in amyloid formation19–22.
MS was used to follow the subunit exchange dynamics of TTR
over several days so that the effect of the two mutations, and that
of tafamidis, on the rate of dissociation of the tetramer species
could be compared. These experiments relied on the use of
hydrogenated (H) and deuterated (D) TTR to track otherwise
identical protein chains. H- and D-TTR were mixed in an equi-
molar ratio and monitored over time to observe the rate of dis-
sociation of the homo-tetramers (4H, 4D) and the rate of
formation of the hetero-tetramers (2H2D, 1H3D, 3H1D; Fig. 1d
and Supplementary Figure 1). The two 2H2D assemblies that can
be formed may have different association constants, given that
one requires only association of homo-dimers while the other
requires the formation of hetero-dimers before assembly into
tetramers. However, these two forms cannot be differentiated by
MS, and are necessarily considered together. Since it has been
shown that the kinetics of TTR subunit exchange is susceptible to
isotope effects18, a deuterated TTR species [(D)S52P] was used as
a reference to allow a meaningful comparison of the TTR var-
iants. The change in relative abundance of each tetrameric species
over time, and the relative association/dissociation rate constants
are shown in Fig. 1e–h.
The dissociation rate of homo-tetramers in the (H)WT-(D)
S52P experiment (Fig. 1e) was 0.20 ± 0.03 day−1. Among the
hetero-tetramer species, those containing identical dimers (2H2D;
two hydrogenated and two deuterated TTR monomers) were
formed at a higher rate (0.33 ± 0.04 day−1) than those formed by
two different dimers (3H1D and 1H3D; 0.14 ± 0.03 day−1). The
observed rate of dissociation of homo-tetramers in the (H)S52P-
(D)S52P experiment (Fig. 1f) was about three times larger than in
the (H)WT-(D)S52P (0.59 ± 0.03 day−1). In this case, however,
the 3H1D/1H3D species were formed faster than the 2H2D ones:
0.83 ± 0.06 day−1 and 0.45 ± 0.01 day−1, respectively. In the (H)
T119M-(D)S52P experiment (Fig. 1g), almost no tetramer
dissociation was observed over the course of eleven days—a
timescale over which essentially all of the TTR would be recycled
in a physiological context (the biological half-life of TTR is
1–2 days23). A final experiment was carried out with (H)S52P and
(D)S52P in the presence of tafamidis at a molar ratio of 1:1
(Fig. 1h). In this case, tetramer dissociation was almost eliminated
by the presence of the drug. This also demonstrated that one
molecule of tafamidis per tetramer was sufficient for effective
stabilisation.
Overall, the MS experiments revealed that the S52P mutation
increases the rate of dissociation of TTR tetramers by about a
factor of three as compared with the WT (reduced tetramer
stability was also observed as a function of pH—see Supplemen-
tary Figure 2a-b). In strong contrast, both the T119M mutation
and tafamidis effectively abolished tetramer dissociation.
Effect of mutations on TTR equilibria. Free energy (G) calcu-
lations were used to study the effects of the T119M and S52P
mutations on the thermodynamic stability of TTR tetramers,
dimers and monomers. These calculations were based on MD
simulations24 and the thermodynamic cycle is shown in Fig. 2.
Control over the potential energy function used allowed specific
residues to be changed into other ones, so that the free energy
change associated with the modifications could be calculated for
the protein in its tetrameric (ΔGtetr), dimeric (ΔGdime) or
monomeric (ΔGmono) states. Differences between these ΔG values
provide an estimate of the stability of the mutant tetramers,
dimers and monomers relative to the WT: ΔΔGtetr,, ΔΔGdime, and
ΔΔGmono respectively (Fig. 2).
The calculations suggested that the S52P mutation would not
have a significant effect on the stability of the tetramers and
dimers for their dissociation to dimers and monomers,
respectively (ΔΔGtetr and ΔΔGdime). However, a large and
statistically significant ΔΔGmono (+ 2.1 kcal mol−1) indicated
that the introduction of the S52P mutation had a destabilising
effect on the monomer with respect to the WT-TTR, correspond-
ing to a shift towards unfolded TTR by a factor of ~34. The
T119M mutation had no effect on the stability of the dimers.
However, in contrast to the case for S52P, a large stabilising effect
on the tetramers was observed (ΔΔGtetr=−8.9 kcal mol−1;
equilibrium constant fold-change of ~3∙106). In addition, the
T119M monomers were calculated to be more stable than WT
monomers by 1 kcal mol−1 (~5-fold increase in stability), a small
but statistically significant effect.
When considering the overall process of tetramer dissociation
and unfolding, the S52P mutation was estimated to shift the
equilibrium toward the unfolded state by 8.1 kcal mol−1 (a
change of ~8∙105), whereas the T119M mutation was estimated to
have the opposite effect of stabilising the tetramers by 12.4 kcal
mol−1 (a change of ~109). Given that the two mutation sites are
not in close contact, it is reasonable to assume additivity for their
associated energetic effects and on this basis the data suggest that
in a double S52P/T119M-TTR mutant, the T119M mutation
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would be able to balance the destabilising effect of the S52P
mutation; this is in agreement with the observed in vivo
protective effect of the T119M mutation25,26.
In summary, the free energy calculations show that the S52P
mutation results in a TTR protein having a less stable fold.
However, this appears to have little direct impact on tetramer
and dimer dissociation. In contrast, the T119M mutation
directly affects tetramer dissociation to dimers by stabilising the
tetramer species and also has the effect of stabilising the protein
fold.
Neutron diffraction reveals the basis of TTR instability. In
order to study the intramolecular interactions of S52P- and
T119M-TTR in atomic detail, room-temperature neutron crys-
tallography studies were carried out. The crystal structures of the
S52P mutant, the T119M mutant, and the S52P mutant in
complex with tafamidis, were determined at resolutions of 1.80 Å,
1.85 Å, and 2.00 Å, respectively. Most of the interaction network
at the monomer–monomer and dimer–dimer interfaces (Sup-
plementary Figure 3), as well as the energetics of bridging water
molecules (Supplementary Figure 4), were found to be conserved
across the WT and mutant structures. However, crucial differ-
ences are identified as the source of the different kinetic and
thermodynamic stabilities observed.
In the T119M structure, the longer Met119 side chain extends
across the thyroxine-binding channel into a hydrophobic pocket
surrounded by residues Leu17, Ala19, Leu110 and Val121
(Supplementary Figure 5). These interactions, as also noted in
previous studies, enhance the association of two dimers and
hence the overall stability of the tetramer27.
The amino acid at position 52 plays a crucial role. In the WT
and the T119M mutant structures, the amide-D and the side-
chain hydroxyl of the Ser52 residue form hydrogen bonds with
OƔ of Ser50, resulting in a stable CD loop (Fig. 3a). The highly
amyloidogenic S52P mutant has a proline residue at position 52
in place of the serine present in the WT. The lack of a main-chain
amide-H and a side-chain hydroxyl group in the proline residue
prevents the formation of two hydrogen bonds and causes a loss
of stability of the protein (Fig. 3b). The distance between amide-N
of residue 52 and Cα of Ser50 in the WT and T119M structures is
4.2 Å (Fig. 3a). The same distance is 0.4 Å wider in the S52P
mutant, implying a looser CD loop (Fig. 3b). This destabilises the
β-turn where the residue is located as well as the associated C and
D strands.
In the S52P/tafamidis complex, the CD loop is not stabilised by
tafamidis binding and the distance between Ser52-N and Ser50-Cα
remains as 4.6 Å. In contrast to the findings of Bulawa et al.28, no
water molecules were found bridging the protein and tafamidis in
this complex. Instead, tafamidis induced a 180° flip to the
Thr119 side chain (Fig. 3c), with the hydroxyl moiety now forming
a hydrogen bond to a water molecule that bridges the two TTR
dimers via Asp18; this was observed in both binding sites.
Interestingly, this water molecule fills the same space that is
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occupied by the Met119 side chain in the non-pathogenic T119M
mutant (Fig. 3d). Grand canonical Monte Carlo calculations29
suggested that the stabilisation of this water molecule upon
tafamidis binding may substantially contribute toward the affinity
of tafamidis, by about −2.8 kcal mol−1 (Supplementary Figure 4).
Collectively, the neutron structures of T119M-TTR, and S52P-
TTR in apo and holo forms, have revealed that most interactions
between the β-strands forming the core of the protein are conserved.
However, the β-turn between the C and D strands is loosened in
S52P-TTR, suggesting that this location is crucial to the reduced
stability of this mutant. The appearance of a bridging water molecule
in the S52P/tafamidis complex results in a conformation that
resembles that of Met119 in T119M-TTR in this region of the
protein, and may provide insight to the mechanism by which the
drug stabilises the TTR tetramer.
Coupling between quaternary and tertiary structure stability.
High-temperature MD simulations were used to study the effect of
TTR quaternary structure on the kinetics of TTR unfolding.
Simulations were carried out at 598 K for the tetramers, dimers
and monomers of WT-TTR with two modern force fields
(Amber99sb*-ILDNP30,31 and Charmm3632). As a measure of
unfolding, the fraction of native contacts Q was employed33,
where 1 indicates a folded protein and 0 an unfolded protein. A
similar metric was used to define the fraction of
monomer–monomer and dimer–dimer interface contacts retained
during the high-temperature simulations (Fig. 3e; Charmm36
results in Supplementary Figure 6). At the temperature of 298 K,
all monomers and interfaces were stable with Q close to one for
simulations of up to 1 μs (Supplementary Figure 7).
In Fig. 3f, the degree of unfolding of TTR monomers over the
course of 100 ns simulations is shown for simulations of the
tetramer, dimer and monomer in solution. The monomer in
solution was found to unfold faster than the monomers that were
part of a dimer, which in turn unfolded faster than the monomers
that were part of the tetramer. Thus, it appeared that the
quaternary structure of TTR had an effect on the stabilisation of
the individual monomeric chains. It is conceivable that the
opposite would hold true as well: i.e., that highly stable
monomeric chains (as in T119M) may enhance the stability of
the tetramer, whereas unstable monomeric chains (as in S52P) are
likely to have a detrimental effect on the stability of the tetramers.
The same effect was observed for the stability of the
monomer–monomer interface. This interface was more resistant
to disruption than the dimer–dimer interface (Fig. 3e). However,
when simulating the TTR dimer, the same interface became much
more easily disrupted within the timeframe of the simulations
(Fig. 3g).
Partial-least squares (PLS) functional mode analysis
(FMA)34,35 was used to identify regions of the TTR protein that
contributed most to its unfolding while being part of a tetrameric
unit. In Fig. 3h, a WT-TTR monomer is shown and colour-coded
according to the root mean square fluctuations of the maximally
correlated mode. The figure shows how the largest loss of native
contacts observed was due to large motions in the C and D
strands (Charmm36 results in Supplementary Figure 8). Similar
observations were also made when calculating the fraction of
native contacts by strand (Supplementary Figure 9).
These MD simulations showed that TTR tertiary structure is
stabilised by the formation of tetrameric and dimeric units.
Similarly, the monomer–monomer interface is stabilised by the
association of TTR dimers into tetramers. Taken together, the
observations explain why tetramer dissociation is the rate-limiting
step in the formation of amyloid. In addition, in agreement with
previous NMR data16,36, PLS-FMA identify the C and D strands as
the regions of TTR tetramers most prone to unfolding.
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Discussion
Based on the data presented, a molecular mechanism that explains
the different behaviours of the T119M and S52P mutants is pro-
posed (Fig. 4). It is suggested that partial unfolding events origi-
nating at the CD strands lead to a parallel equilibrium of folded
and partially unfolded TTR states (tetramers, dimers and mono-
mers) that allows the effects of the S52P and T119M mutations to
be rationalised in the context of the current and previous
experimental observations13,16,36,37. Given that a number of other
pathogenic mutations are located on the C and D strands (e.g.
L55P, S50R, E54G), the mechanism proposed here may apply to
other mutations in this region of the protein8,13,38,39.
S52P-TTR tetramers were observed to dissociate faster than the
WT in solution. However, no thermodynamic or structural cause
for a direct destabilisation of S52P tetramers could be established
from these observations or from those published previously. In
contrast, the free energy calculations described here provide
evidence that the tertiary structure of S52P-TTR is thermo-
dynamically less stable than that of the WT. This, together with
structural (neutron diffraction) and dynamical (simulation) evi-
dence of a loose CD loop, suggests that unfolding events at the
CD strands are likely. As it is expected that a partially unfolded
TTR would proceed towards dissociated species and amyloid
formation faster than the corresponding fully folded protein
(Fig. 4a), this parallel equilibrium can explain the high amount of
amyloid fibrillation of S52P-TTR (Supplementary Figure 2c) as
well as the faster tetramer dissociation rates observed.
T119M-TTR tetramers were found to be highly resistant to
dissociation. The free energy calculations estimated a stabilising
effect of 8.9 kcal mol−1 on the tetramer, which corresponds to a
change in equilibrium constant of ~3∙106. This effect can be
understood in terms of the increased contact area between the
two dimers, which stabilises the dimer–dimer interface (Supple-
mentary Figure 5). In addition, the free energy calculation results
suggest a tertiary fold in T119M-TTR that is more stable than in
the WT by about 1 kcal mol−1. As illustrated in Fig. 4b, tetramer
stabilisation directly reduces the population of amyloidogenic
building blocks. Furthermore, a stable tertiary structure can
protect against the unfolding of monomeric TTR. Finally, the
coupling between TTR quaternary structure and the stability of
the TTR fold suggested by the simulations indicates that the
highly stable T119M-TTR tetramer reduces the probability of the
CD strands unfolding (Fig. 4b).
Stabilisation of the native tetrameric structure by small mole-
cule binding to the T4 binding sites of TTR is a well-cited
rationale for the inhibition of TTR amyloidogenesis40. MS kinetic
experiments have shown how tafamidis, like the T119M muta-
tion, strongly inhibits tetramer dissociation. The binding affinity
of tafamidis to TTR quantifies the stabilising effect of the drug on
TTR tetramers, and was measured to be ~12 kcal mol−1 (Kd1= 2
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the change in the fraction of native contacts for the high-temperature simulations
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08609-z ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:925 | https://doi.org/10.1038/s41467-019-08609-z | www.nature.com/naturecommunications 5
nM)28. The stabilising effect of T119M on the tetramer (with
respect to the dimer) was found to be about 9 kcal/mol. However,
considering the further gains in TTR fold stability conferred by
the mutation (ΔΔGT119M (mono)), the overall thermodynamic
effect is very similar to that of the tafamidis-S52P complex, with
ΔΔGT119M (unf) ≈−12 kcal mol−1. Tafamidis therefore stabilises
native TTR thermodynamically and kinetically in a manner that
is comparable to T119M. However, it is difficult to predict the
extent to which the two separate effects of tetramer and fold
stabilisation may impact on the in vivo protection against amy-
loidogenesis. Structurally, the binding of tafamidis results in the
reorientation of Thr119 and the emergence of a water molecule in
the binding pocket. This water molecule is located in the same
position as the side chain of Met119 in the T119M mutant.
The results presented also suggest that TTR tetramers have a
stabilising effect on the monomer–monomer interface, which
becomes weakened when TTR is in its dimeric form (Fig. 3g).
Thus, even though the monomer–monomer interface is more
stable than the dimer–dimer interface16,41 when the tetramer is
intact, the loss of native quaternary structure can destabilise the
monomer–monomer interface such that TTR dimers are able to
quickly proceed to further dissociation into monomers
(in agreement with the data described here and elsewhere22,42).
This observation further explains why tetramer dissociation is the
rate-limiting step in the formation of amyloid. It is noted that
dissociation might not be the only factor causing the formation of
TTR fibrils (e.g. seeding with ex vivo fibrils has been found to
promote the formation of fibrils in vitro) but it is a necessary
one43.
Finally, a number of studies44–47 have identified a TTR frag-
ment (residues 49–127) in ex vivo amyloid fibrils. This fragment
is formed by proteolytic cleavage of the peptide bond between
Lys48 and Thr49, with the S52P mutant being particularly sus-
ceptible to it45,47. Within the mechanism set out in Fig. 4, the
higher rate of proteolytic cleavage in S52P-TTR can be explained
by an increased accessibility to Lys48 due to a higher propensity
to unfold at the CD strands. Cleavage of the unfolded structure
causes an irreversible transition to a partially unfolded state, thus
preventing refolding and ultimately enhancing the rate of fibril
formation.
In summary, the results described here provide novel structural
and dynamical insights into the opposing effects of the S52P and
T119M mutations in TTR, as well as the effects of tafamidis
binding on the stability of TTR. The results provide molecular
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Fig. 4 Proposed model of mutational effect on TTR stability. Shorter arrows indicate a lower propensity to association/folding. Red arrows reflect the
qualitative change in reaction rates for the mutants with respect to WT-TTR. a The S52P mutation increases the likelihood of partial and full unfolding of
TTR monomeric units. This, in turn, also leads to a lower stability of TTR multimeric assemblies; hence partially unfolded dimers and monomers, and fully
unfolded monomers, are generated at a higher rate. Some or all of these species are then removed from solution via the formation of amyloid fibrils. b In
contrast to S52P, the T119M mutation stabilises the folded monomeric forms of TTR. Most importantly, this mutation has a large stabilising effect on TTR
tetramers, which are believed not to form fibrils. Furthermore, it is proposed that the higher stability of the tetramer also has the effect of further stabilising
the monomer fold
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level detail of direct relevance to TTR amyloidogenicity, and have
provided a framework for further investigation into the effects of
residue mutation on TTR’s states and their equilibria, and for the
development of novel targeted therapies for FAP and SSA.
Methods
Protein preparation and crystallization. The cDNA corresponding to the gene
coding for the 127 amino acids of human transthyretin (TTR) protein was cloned
into a pET-M11 vector encoding an N-terminal His6 tag and a TEV cleavage site
(EMBL Protein and Purification Facility, Germany) and then expressed in E.coli
BL21 (DE3) cells (Invitrogen). The S52P and T119M mutants were generated using
QuikChange Lightning Multi Site-Directed Mutagenesis kit (Strategene). WT-TTR
cDNA sequence and the sequences of primers used for S52P and T119M mutations
are shown in Supplementary Table 1. Deuterated protein was produced in the
Deuteration Laboratory (D-Lab) platform within ILL's Life Sciences Group48. Cells
were adapted to perdeuterated Enfors minimal medium and grown in a fed-batch
fermenter culture at 30 °C using d8-glycerol (99% deuterium; Euriso-top) as the
only carbon source. H-TTRs and D-TTRs were purified in an identical manner.
Cell paste was resuspended homogeneously in lysis buffer (20 mM Tris pH 8, 250
mM NaCl, 3 mM imidazole) in the presence of EDTA-free protease inhibitor
cocktail (Roche). The cells were lysed by ultrasonication on ice at 50% amplitude
and 25 sec pulses. The lysate was cleared by centrifugation at 18,000 rpm at 4 °C for
30 min. The supernatant containing crude protein extracts was recovered and
purified using benchtop gravity-flow chromatography. Nickel-nitriloacetic acid
(Ni2+-NTA) resin was pre-washed with lysis buffer and left in incubation with the
protein at 4 °C for at least an hour to increase binding efficiency. The protein/resin
mix was then loaded into 10 ml disposable column. The column was washed three
times with wash buffer (20 mM Tris pH 8, 15 mM imidazole, NaCl at 500 mM, 1
M, and 250 mM, respectively) before the protein was eluted (elution buffer: 20 mM
Tris pH8, 250 mM NaCl, 250 mM imidazole). Fractions containing protein were
then pooled together for TEV protease treatment to remove His6-tag and dialysed
into gel filtration buffer (10 mM Tris pH 7.5, 50 mM NaCl, 1 mM DTT) overnight
at 4 °C. Protein was separated from the cleaved poly-histidine tail using the same
gravity-flow column described above. Flowthrough from the column was con-
centrated, filtered (with 0.22 μmmembrane pore size) and loaded onto Superdex 75
HiLoad 16/600 gel filtration column (GE Healthcare) running at 1 ml/min at room
temperature. Peak fractions were pooled and concentrated using Amicon Ultra
centrifugal filter units (Millipore) and stored at −20 °C. Analysis was carried out on
12% Tris-Tricine gel after each step of purification to monitor the purity of the
protein. The details of the expression and purification have been described pre-
viously18,49. While the deuterated TTR was expressed under conditions where only
deuterium atoms were present, protiated (1H-based) solutions were used during
purification. Prior to protein crystallization, the purified protein was buffer-
exchanged using a deuterated solution so that the labile protium atoms acquired
during the purification steps that involved hydrogenated solutions were replaced by
deuterium. Tafamidis (HPLC purity: ≥ 98%; Carbosynth Limited, U.K.) was dis-
solved in 100% deuterated dimethyl sulfoxide (D-DMSO) for crystallization. All
crystals were grown by sitting-drop vapour diffusion at 18 °C using deuterated
protein and deuterated solution. The TTR S52P mutant crystal (~0.60 mm3) were
grown in 1.9 M malonate pD 6.4 with a protein concentration of 25 mg/ml (drop
volume 50 µl; protein-to-buffer ratio of 7:5), while the T119M mutant crystal
(~0.80 mm3) were in 1.9 M malonate pD 5.9 with 40 mg/ml protein concentration
(drop volume 50 µl; protein-to-buffer ratio of 1:1). For the crystal of the S52P/
tafamidis complex (~0.11 mm3), a protein concentration of 20 mg/ml and tafa-
midis concentration of 678 μM in 10% D-DMSO (protein-to-ligand molar ratio of
1:2) were used (drop volume 40 µl; protein-to-buffer ratio of 1:1). For neutron data
collection, the crystals were mounted in quartz capillaries and surrounded by a
small amount of mother liquor from the crystallization well. The capillaries were
sealed tightly using wax to eliminate the diffusion of gas and atmospheric water.
Neutron data collection and processing. Details of the neutron data collection
for WT-TTR have been reported by Haupt et al49. Neutron quasi-Laue diffraction
data from the crystals of the S52P mutant and the S52P/tafamidis complex were
collected at room temperature using the LADI-III diffractometer50 at the Institut
Laue-Langevin (ILL), Grenoble. For the S52P mutant, a neutron wavelength range
(Δλ/λ= 30%) of 2.9–3.9 Å was used, with data extending to 1.8 Å resolution. As is
typical for a Laue experiment, the crystal was held stationary at different φ (vertical
rotation axis) settings for each exposure. A total of 26 images (exposure time of 12
h per image) were collected from two different crystal orientations. For the S52P/
tafamidis complex, a neutron wavelength range of 2.7–3.6 Å was used with data
extending to 2.0 Å resolution. In total, 13 images were collected (exposure time of
8 h per image) from three different crystal orientations. The neutron diffraction
images were indexed and integrated using the LAUE suite program LAUEGEN51.
The program LSCALE52 was used to determine the wavelength-normalisation
curve using the intensity of symmetry-equivalent reflections measured at different
wavelengths and to apply wavelength-normalisation calculations to the observed
data. The data were then merged in SCALA53. Relevant data collection statistics are
summarised in Supplementary Table 2.
Neutron monochromatic diffraction data for the T119M mutant crystal were
collected at room temperature using the instrument BIODIFF54 operated by the
Forschungsreaktor München II (FRM II) and the Jülich Centre for Neutron Science
(JCNS) at Garching. For data collection, the wavelength was set at 2.67 Å (Δλ/λ=
2.9%). A total of 202 frames were recorded with a rotation range of 0.35° and an
exposure time of 53 min per frame. The diffraction data were indexed, integrated
and scaled using HKL200055 to a resolution of 1.85 Å. The output file of HKL2000
in SCA format was converted into MTZ format by using scalepack2mtz program in
the CCP4 suite56. Relevant data collection statistics are summarised in
Supplementary Table 2.
X-ray data collection and processing. X-ray diffraction data of the crystals of all
three variants were recorded on beamline ID30B57 at the European Synchrotron
Research Facility (ESRF), Grenoble using a heavily attenuated X-ray beam (1.96%
for S52P; 19.17% for T119M; 9.83% for S52P/tafamidis) of wavelength 0.9763 Å. For
S52P and S52P/tafamidis complex, the same crystals used for data collection at
LADI-III was used; whereas for T119M, a crystal from the same crystallization drop
as the one used at BIODIFF was used. Data were recorded at room temperature on
capillary-mounted crystals. Data were processed to the same maximum resolution
of the corresponding neutron data with XDS58, scaled and merged with SCALA53,
and converted to structure factors using TRUNCATE in the CCP4 suite56. Relevant
data collection statistics are summarised in Supplementary Table 2.
Joint neutron and X-ray structure refinement. The PDB structures 5CLX
(refined X-ray models of TTR S52P; data collection at 100 K) was used as starting
models for joint X-ray and neutron refinement against the datasets of S52P and
S52P/tafamidis; and 5CM1 (refined X-ray models of TTR T119M; data collection at
100 K) was used for the datasets of T119M. The phenix.refine program59 in the
PHENIX package60 was used for refinement. The preparation of the starting model,
the refinement settings and workflow, and the modelling of solvent molecules were
as detailed in Haupt et al.41. Using the ReadySet option in PHENIX60, exchangeable
hydrogen and deuterium atoms were placed at appropriate sites of the protein
models with deuteriums elsewhere. For positions where both hydrogen and deu-
terium atoms were modelled, the occupancies of both were set to 0.5 and then their
occupancies were refined, with their total occupancy constrained to 1. D2O
molecules were added using ReadySet based on the positive neutron scattering
length density in Fo–Fc maps. Coot61 was used for model modifications, such as
addition of solvent molecules, and rotamer- and torsion-angle adjustments,
according to positive and negative nuclear scattering length density in both 2Fo–Fc
and Fo–Fc maps. The final refinement statistics are summarised in Supplementary
Table 3.
Monitoring subunit composition of tetrameric TTR by native MS. The details
of the instrumental arrangements and sample preparation protocols have been
described previously18. MS analyses were carried out on a quadrupole time-of-flight
mass spectrometer (Q-TOF Ultima, Waters Corporation, Manchester, U.K.) that
was modified for the detection of high masses62,63. As has been tested previously18,
experiments carried out at 4 °C in static (non-shaking) conditions provided well-
resolved MS spectra, hence these conditions were used for the work described here.
Prior to native MS analysis, proteins were buffer-exchanged into 250mM ammo-
nium acetate pH 7. All the labile sites (i.e. N- and O-bound deuterium atoms) were
allowed to exchange from D to H. The mass difference between (H)TTR and (D)
TTR was contributed by carbon-bound Ds that were incorporated into the amino
acid chain during synthesis and were non-exchangeable. Subunit exchange was
initiated by mixing a solution containing one unlabelled protein variant and one
with deuterium-labelled protein variant at 1:1 molar ratio. A concentration of 3 μM
for each protein tetramer solution was used for all experiments. The relative
abundance of the tetramers was calculated from the peak area of the 13+ to 15+
charge states and expressed as a percentage of the total area of the peaks assigned to
the tetrameric TTR. For the experiment of mixing HS52P and DS52P in the pre-
sence of tafamidis, tafamidis was in 0.5% DMSO at a TTR:tafamidis molar ratio of
1:1. In this case, the relative abundance was calculated from the peak area of the 12
+ to 14+ charge states. The presence of DMSO resulted in broader peaks on the
MS spectra and less charge on the protein particles. The MS data were fitted by
Bayesian regression using a first order kinetics model.
Native MS data fitting and parameter estimation. Bayesian regression of the
native MS data was performed in python using the PyMC3 library64. The following
one-phase exponential decay model was used:
yðtÞ ¼ cþ ðy0  cÞekt ð1Þ
where t is the time (in minutes), y(t) is the relative abundance of each species (in
percentage), y0 is the abundance at t= 0, c is the abundance at t=∞ and k the rate
constant (in inverse minutes); c < y0 for dissociating species, and c > y0 for asso-
ciating species. For y0, a normally distributed prior was used, with mean 50% and
standard deviation of 15% for dissociation, and with mean of 0% and standard
deviation of 5% for association. For c, a uniform prior between 0% and y0 was used
for dissociation, and between y0 and 100% for association. For k, a half normal
prior with mean of 0 min−1 and standard deviation of 10 min−1 was used. White
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noise was modelled with a half normal prior with zero mean and standard
deviation of 10%. The posterior estimate of the parameters was obtained by
drawing 10,000 Markov chain Monte Carlo (MCMC) samples with the No-U-Turn
Sampler (NUTS) algorithm. Five thousand tuning steps were carried out and
discarded before colleting the posterior samples used for the estimate. The max-
imum a posteriori estimate (MAP) of the parameter space was passed to the
sampler as the starting value. The mean and standard deviation of the rate con-
stants (k) from their posterior distributions are reported.
High-temperature molecular dynamics simulations. Molecular dynamics (MD)
simulations were performed with Gromacs 201665. The starting structure for the
simulations was the WT (PDB-ID 4PVM) variant of TTR protonated at pH 7 with
pdb2gmx. The dimeric and monomeric models were obtained from the same
neutron crystal structure: for the dimers, chains A and B were used, and for the
monomers chain A was used. The protein was modelled with the Amber99SB*-
ILDNP30,31 and the Charmm36 (Nov. 2016)32 force field, and water molecules with
the TIP3P model66. The protein was solvated in a dodecahedral box with periodic
boundary conditions and a minimum distance between the solute and the box of
12 Å. Sodium and chloride ions were added to neutralise the systems at the con-
centration of 0.15M.
Energy minimisation was performed using a steepest descent algorithm with
force tolerance of 10 kJ mol−1 nm−1 for a maximum of 10,000 steps. 1 ns NVT and
then NPT equilibrating simulations were performed with all solute heavy atoms
restrained with a force constant of 1000 kJ mol−1 nm−2. In these simulations, the
temperature was coupled with the stochastic v-rescale thermostat by Bussi et al.67.
at the target temperature of 298 K; the pressure was controlled with the Berendsen
weak coupling algorithm68 at a target pressure of 1 bar. A leap-frog integrator was
used with a time-step of 4 fs and virtual sites69 were used for all solute hydrogens.
All bonds were constrained with the P-LINCS algorithm70. The particle mesh
Ewald (PME) algorithm71 was used for electrostatic interactions with a real space
cut-off of 12 Å. The Verlet cut-off scheme was used with a Lennard–Jones
interaction cut-off of 12 Å and a buffer tolerance of 0.005 kJ mol−1 ps−1. For the
production simulations at 298 K, a single unbiased 1 μs simulation in the NPT
ensemble was performed using the Parrinelo–Rahman pressure coupling scheme72.
For the simulations at 598 K, ten simulations of 100 ns were performed in the NVT
ensemble. Coordinates were saved every 50 ps.
The fraction of native contacts (Q), as described by Best et al.33, was employed
as a measure of the degree of protein (un)folding and native-likeness of
protein–protein interfaces. When used to describe protein folding, the list of native
contacts was built by taking all pairs of heavy atoms i and j that are within 4.5 Å of
each other and are on two different residues separated by at least three other
residues. When describing protein–protein interfaces, the original definition of the
authors was adapted so that the list of native contacts included all pairs of heavy
atoms (i, j) that are within 4.5 Å of each other and are on two different protein
chains. Once the set of atom pairs is defined, Q is then calculated as follows:
QðxÞ ¼ 1
N
X
ði;jÞ2N
1
1þ exp½βðri;j xð Þ  λr0i;jÞ ð2Þ
where N is the number of atom pairs (i,j) forming the native contacts, ri,j(x) is the
distance between atom i and atom j in the configuration x, r0i;j is the distance
between i and j is the native state (i.e. the starting neutron crystal structure used), β
is a smoothing parameters with value of 5 Å−1 and λ is a factor that accounts for
fluctuations that takes the value of 1.8 for atomistic simulations. MD trajectories
were analysed and Q calculated with scripts written in python and using the mdtraj
library73.
Partial Least-Squares Functional Mode Analysis (PLS-FMA)34,35 was performed
on the main chain of the proteins and using the fraction of native contacts as the
functional property of interest. In particular, we analysed with PLS-FMA the
trajectories of the tetramer simulations, using the fraction of native contacts of each
monomeric unit as the measure of unfolding. About 75% of simulation snapshots
were used for training and 25% for validation. The model was built using 20 PLS
components, which resulted in a Pearson correlation coefficient between the data
and the model ≥ 0.97 for both the training and the validation sets, for both force
fields. We refer to the ensemble weighted maximally correlated mode (ewMCM) as
described Krivobokova et al.35 simply as the PLS-FMA mode.
Free energy calculations of protein mutation. Alchemical free energy calculations
were performed using Gromacs 201665 and a custom version of Gromacs 4.6 that
implements the soft-core potential proposed by Gapsys et al.74. The input hybrid
topologies were generated using the pmx python tool75. The starting structures for
the calculations were the WT-TTR (PDB-ID 4PVM), S52P-TTR (PDB-ID 5NFW)
and T119M-TTR (PDB-ID 5NFE) protonated at pH 7 with pdb2gmx. The dimeric
and monomeric starting structures were obtained from the same neutron structures;
for the dimers, chains A and B were used, and for the monomers chain A was used.
The unfolded proteins were modelled as capped tripeptides, where the central
amino acid was the one being mutated, and the other two were the adjacent amino
acids in protein sequence. Proteins were modelled with the Amber99SB*-ILDNP
force field30,31 and water molecules with the TIP3P model66. The proteins were
solvated in a dodecahedral box with periodic boundary conditions and a minimum
distance between the solute and the box of 12 Å. Sodium and chloride ions were
added to neutralise the systems at the concentration of 0.15M.
Energy minimisation was performed using a steepest descent algorithm for a
maximum of 10,000 steps. Temperature and pressure were equilibrated with ten
independent 0.5 ns simulations in the NPT ensemble, with all solute heavy atoms
restrained with a force constant of 1000 kJ mol−1 nm−2. A leap-frog stochastic
dynamics integrator76 was used with time-step of 2 fs; temperature was coupled
using Langevin dynamics at the target temperature of 298 K, and pressure with the
Berendsen weak coupling algorithm68 at a target pressure of 1 bar. The particle
mesh Ewald (PME) algorithm71 was used for electrostatic interactions with a real
space cut-off of 11 Å, a spline order of 4, a relative tolerance of 10−5 and a Fourier
spacing of 1.2 Å. The Verlet cut-off scheme was used with a Van der Waals
interaction cut-off of 11 Å and a buffer tolerance of 0.005 kJ mol−1 ps−1. Bonds
involving hydrogens were constrained with the P-LINCS algorithm70. Ten
equilibrium simulations of 10 ns duration were then initiated from the last frame of
the short (0.5 ns) equilibration simulations. From each of the ten equilibrium
simulations, a non-equilibrium trajectory was spawn every 0.2 ns, for a total 50
trajectories per equilibrium simulation and 500 trajectories overall. Forward and
reverse transformations were performed for both mutants, with 500 non-
equilibrium trajectories per transformation: WT→S52P, S52P→WT, WT→T119M,
T119M→WT. Coordinates for hybrid residues were built with pmx75 after
extracting the starting configurations of the systems. Energy minimisation was
performed on the dummy atoms only, before equilibrating velocities with a 10 ps
simulation. Then, the non-equilibrium alchemical transformation was performed
over 100 ps. The non-equilibrium simulations were performed using a custom
version of Gromacs 4.6 that implements the soft-core potential described in Gapsys
et al.74, where both vdW and Coulombic interactions were soft-cored. Free energy
differences were estimated using the Bennet’s Acceptance Ratio (BAR)77 as
implemented in pmx75. Uncertainties in the ΔG values were calculated by taking
the standard error of the BAR estimate from the ten independent equilibrium
simulations and related non-equilibrium trajectories.
Grand canonical monte carlo calculations. The simulation package ProtoMS 3.3
was used for Grand Canonical Monte Carlo (GCMC) calculations and data ana-
lysis29,78. The starting tetramer structures for the calculations were the WT-TTR
(PDB-ID 4PVM), S52P-TTR (PDB-ID 5NFW), S52P-TTR/tafamidis (PDB-ID
6FFT) and T119M-TTR (PDB-ID 5NFE) with protonation states as resolved
experimentally. Proteins were modelled with the Amber ff14SB force field79, water
with the TIP3P model, and tafamidis with the GAFF/AM1-BCC force field66,80.
For the calculation of the stability of W17, a GC box was created around the
water molecule by adding 2 Å padding in all three dimensions and used for both
the calculations in S52P-TTR and S52P-TTR/tafamidis. For the calculation of the
monomer–monomer interface hydration free energy, the grand canonical box was
defined so to encompass the interface containing the conserved water molecules of
interest; the same box was used for all proteins, which had been previously aligned.
Because the hydration free energy results might be sensitive to the protonation state
of the histidine residues in proximity of these conserved water molecules, from
each experimental structure we generated the other two proteins by mutating the
amino acids at positions 52 and 119. Thus, for each TTR variant, we performed
three sets of calculations, based on each neutron structure and its respective
protonation states of His31, His56, His88 and His90.
Protein residues that were further than between 16 and 20 Å away from the
grand canonical region were removed, with the exact distance chosen to retain
whole residues. The systems were then solvated up to a radius of 30 Å around the
grand canonical region. All simulations were carried out at 298 K, and a 10 Å cut
off was applied to the non-bonded interactions. Before initiating the GCMC
simulations, the systems were equilibrated using 50 million (M) solvent-only
moves in the canonical ensemble, so to equilibrate the water around the proteins.
Water molecules present in the pre-defined GCMC box were then removed; this set
of coordinates represented the starting point of the GCMC simulations.
For the calculation of the monomer–monomer interface hydration, a set of
32 simulations were performed at a range of Adams values from −29 to+ 2 at unit
increments. For the calculations of the stability of W17, Adams values between
−18 and 0 were used instead. For each window, 15 M equilibration moves were
performed only on the grand canonical solute, with insertion, deletion and
translation/rotation moves generated at the same ratio. An additional 5 M
equilibration moves followed where the protein and solvent molecules were also
sampled, before starting the production simulation of 50 M moves. Half of the MC
moves were dedicated to the grand canonical water molecules, and the other half
was split between protein residues and solvent in proportion to the number of
solvent molecules and protein residues, according to the ratio of 1:5. Hamiltonian
exchange was employed78, with exchanges being performed every 0.2 M steps. Data
for analysis, energies, number of GC solutes present, and coordinates were saved to
file every 0.1 M moves.
The above procedure was repeated three times for the monomer–monomer
interface hydration calculation (i.e. 9 calculations for each TTR variant, three
repeated calculations per starting structure) and ten times for the W17 stability
calculation. The hydration free energy of the whole grand canonical region, and the
binding free energy of individual water molecules, were computed using grand
canonical integration (GCI) as described in Ross et al.29. GCI was performed using
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08609-z
8 NATURE COMMUNICATIONS |          (2019) 10:925 | https://doi.org/10.1038/s41467-019-08609-z | www.nature.com/naturecommunications
the calc_gci.py script that is part of the ProtoMS 3.3 tools, with the data from all
repeats being analysed together. The amount of data discarded as equilibration was
determined using the equilibration detection tool available in calc_series.py. The
same amount of data was discarded from all windows after determining the average
number of moves needed for equilibration.
Data availability
Atomic coordinates and diffraction data have been deposited in the Protein Data Bank
(accession codes 5NFW for S52P-TTR, 5NFE for T119M-TTR, and 6FFT for S52P-TTR/
tafamidis complex). Other data are available from the corresponding author upon rea-
sonable request.
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